AU697876B2 - New erythromycin derivatives, their preparation process and their use as medicaments - Google Patents

New erythromycin derivatives, their preparation process and their use as medicaments Download PDF

Info

Publication number
AU697876B2
AU697876B2 AU40324/95A AU4032495A AU697876B2 AU 697876 B2 AU697876 B2 AU 697876B2 AU 40324/95 A AU40324/95 A AU 40324/95A AU 4032495 A AU4032495 A AU 4032495A AU 697876 B2 AU697876 B2 AU 697876B2
Authority
AU
Australia
Prior art keywords
radical
product
formula
methanol
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU40324/95A
Other languages
English (en)
Other versions
AU4032495A (en
Inventor
Constantin Agouridas
Jean-Francois Chantot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Hoechst Marion Roussel
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel, Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel
Publication of AU4032495A publication Critical patent/AU4032495A/en
Assigned to HOECHST MARION ROUSSEL reassignment HOECHST MARION ROUSSEL Alteration of Name(s) of Applicant(s) under S113 Assignors: ROUSSEL-UCLAF
Application granted granted Critical
Publication of AU697876B2 publication Critical patent/AU697876B2/en
Assigned to AVENTIS PHARMA S.A. reassignment AVENTIS PHARMA S.A. Alteration of Name(s) in Register under S187 Assignors: HOECHST MARION ROUSSEL
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08Hetero rings containing eight or more ring members, e.g. erythromycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU40324/95A 1994-12-09 1995-12-08 New erythromycin derivatives, their preparation process and their use as medicaments Expired AU697876B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9414807A FR2727969B1 (fr) 1994-12-09 1994-12-09 Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR9414807 1994-12-09

Publications (2)

Publication Number Publication Date
AU4032495A AU4032495A (en) 1996-06-20
AU697876B2 true AU697876B2 (en) 1998-10-22

Family

ID=9469625

Family Applications (1)

Application Number Title Priority Date Filing Date
AU40324/95A Expired AU697876B2 (en) 1994-12-09 1995-12-08 New erythromycin derivatives, their preparation process and their use as medicaments

Country Status (14)

Country Link
US (1) US5786339A (de)
EP (1) EP0716093B1 (de)
JP (1) JP4083824B2 (de)
KR (1) KR100371473B1 (de)
CN (1) CN1067077C (de)
AT (1) ATE172467T1 (de)
AU (1) AU697876B2 (de)
CA (1) CA2164798C (de)
DE (1) DE69505487T2 (de)
DK (1) DK0716093T3 (de)
ES (1) ES2123934T3 (de)
FR (1) FR2727969B1 (de)
HU (1) HU215192B (de)
ZA (1) ZA9510447B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2745290B1 (fr) * 1996-02-28 1998-04-03 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
USRE38520E1 (en) * 1996-02-28 2004-05-18 Aventis Pharma S.A. Erythromycin derivatives, method for preparing same, and use thereof as drugs
DE19652362A1 (de) 1996-12-17 1998-06-18 Thomson Brandt Gmbh Verfahren und Vorrichtung zur Kompensation der durch die Verarbeitung von Chrominanz-Signalen entstehenden Luminanzdefekte
US5972898A (en) * 1998-03-27 1999-10-26 Abbott Laboratories 3',3-N-bis-substituted macrolide LHRH antagonists
US5955440A (en) * 1998-03-27 1999-09-21 Abbott Laboratories Macrolide LHRH antagonists
US6020521A (en) * 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
US6387885B1 (en) * 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
DE69926005T2 (de) 1998-09-22 2006-05-18 Pfizer Products Inc., Groton Carbamat- und carbazatketolidantibiotika
FR2785612A1 (fr) * 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2786188B1 (fr) * 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
EP1137654A1 (de) 1998-12-10 2001-10-04 Pfizer Products Inc. Carbamat- und carbazat-ketolide antibiotika
HUP0105190A3 (en) * 1999-01-27 2003-03-28 Pfizer Prod Inc Ketolide antibiotics, medicaments containing them and their use
CN1351608A (zh) * 1999-05-24 2002-05-29 辉瑞产品公司 13-甲基红霉素衍生物
WO2001010878A1 (fr) * 1999-08-06 2001-02-15 Taisho Pharmaceutical Co., Ltd. Derives d'erythromycine a
AU6183800A (en) * 1999-08-06 2001-03-05 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
AU6316400A (en) * 1999-08-06 2001-03-05 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
ID27331A (id) * 1999-09-29 2001-03-29 Pfizer Prod Inc Pembuatan antibiotik-antibiotik ketolida karbamat
TWI292316B (en) * 1999-10-11 2008-01-11 Sod Conseils Rech Applic Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof
EP1146051A3 (de) * 2000-04-10 2001-10-31 Pfizer Products Inc. Erythromycin A-Derivate
US20050014706A1 (en) * 2003-07-14 2005-01-20 Kanakeshwari Falzari Method of treating tuberculosis
WO2006080954A1 (en) * 2004-07-28 2006-08-03 Ranbaxy Laboratories Limited Ketolide derivatives as antibacterial agents
PT1836211E (pt) * 2004-12-21 2010-04-08 Pfizer Prod Inc Macrólidos
US10130465B2 (en) 2016-02-23 2018-11-20 Abbott Cardiovascular Systems Inc. Bifurcated tubular graft for treating tricuspid regurgitation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL114589A (en) * 1990-11-21 1999-12-22 Roussel Uclaf Intermediates for the preparation of the history of erythromycin
FR2692579B1 (fr) * 1992-06-19 1995-06-02 Roussel Uclaf Nouveaux dérivés de la picromycine, leur procédé de préparation et leur application comme médicaments.
US5527780A (en) * 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2697524B1 (fr) * 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
HRP930014A2 (en) * 1993-01-08 1994-08-31 Pliva Pharm & Chem Works 9-deoxo-9a-aza-11-deoxy-9a-homoeritromycin a 9a, 11-cyclic carbamates
JPH07219312A (ja) * 1993-12-10 1995-08-18 Canon Inc 画像形成装置

Also Published As

Publication number Publication date
FR2727969B1 (fr) 1997-01-17
CA2164798C (fr) 2007-03-20
JP4083824B2 (ja) 2008-04-30
US5786339A (en) 1998-07-28
ES2123934T3 (es) 1999-01-16
EP0716093A1 (de) 1996-06-12
HUT74075A (en) 1996-10-28
EP0716093B1 (de) 1998-10-21
JPH08231583A (ja) 1996-09-10
HU215192B (hu) 1998-10-28
HU9503524D0 (en) 1996-02-28
FR2727969A1 (fr) 1996-06-14
CN1133291A (zh) 1996-10-16
ATE172467T1 (de) 1998-11-15
KR960022553A (ko) 1996-07-18
KR100371473B1 (ko) 2003-07-22
CA2164798A1 (fr) 1996-06-10
ZA9510447B (en) 1996-12-09
DE69505487D1 (de) 1998-11-26
CN1067077C (zh) 2001-06-13
AU4032495A (en) 1996-06-20
DE69505487T2 (de) 1999-05-12
DK0716093T3 (da) 1999-06-28

Similar Documents

Publication Publication Date Title
AU697876B2 (en) New erythromycin derivatives, their preparation process and their use as medicaments
AU716204B2 (en) Novel erythromycin derivatives, method for preparing same, and use thereof as drugs
AP587A (en) New erythromycin derivatives, their preparation process and their use as medicaments.
AU670329B2 (en) New derivatives of erythromycin, their preparation process, their use as medicaments
JP2992540B2 (ja) 新規なエリスロマイシン誘導体、それらの製造法及び薬剤としての使用
JP2001520234A (ja) 9a−アザリド類から誘導される新規3,6−ヘミケタール類
JP4573925B2 (ja) 新規のエリスロマイシン誘導体、その製造方法及びその薬剤としての使用
JP5188520B2 (ja) 新規なエリスロマイシン誘導体、製造方法及び医薬としての利用
AP997A (en) Novel erythromycin derivatives, method for preparing them and their use as medicine.
AP1078A (en) Novel erythromycin derivatives, method for preparing same and use thereof as drugs.
AU712665B2 (en) New aromatic derivatives substituted by a ribose, their preparation process and their use as medicaments
JP4864184B2 (ja) 5−デスオサミニルエリスロノリドaの新規の2−ハロゲン化誘導体、それらの製造方法及び薬剤としてのそれらの使用
AU761551B2 (en) Novel 6-deoxy erythromycin derivatives, method for preparing same and use as medicines
USRE38520E1 (en) Erythromycin derivatives, method for preparing same, and use thereof as drugs
EP0874863A1 (de) 3-deoxy-3-descladinosederivate von erythromycin a und b
MXPA99005840A (en) Novel erythromycin derivatives, method of preparation and application as medicines
MXPA99005226A (en) Novel erythromycin derivatives, method for preparing them and their use as medicine
MXPA00003644A (en) NOVEL 3,6-HEMIKETALS FROM THE CLASS OF 9a-AZALIDES

Legal Events

Date Code Title Description
PC Assignment registered

Owner name: AVENTIS PHARMA S.A.

Free format text: FORMER OWNER WAS: HOECHST MARION ROUSSEL